In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3952-3954

  Trilles, Luciana ^a   Fernández Torres, Belkys ^b   Dos Santos Lazéra, Márcia ^a   Wanke, Bodo ^a   De Oliveira Schubach, Armando ^a   De Almeida Paes, Rodrigo ^a   Inza, Isabel ^b   Guarro, Josep ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; EBERCONAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG SENSITIVITY; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; TEMPERATURE DEPENDENCE; YEAST;

ANTIFUNGAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; SPOROTHRIX; SPOROTRICHOSIS; TEMPERATURE;

EID: 24144437386     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3952-3954.2005     Document Type: Article

References (22)

1. -1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47:62-68.
2. Conti, I. A. 1989. Epidemiology of sporotrichosis in Latin America. Mycopathologia 108:113-116.
3. Conti, I. A., E. Civila, and E. Gezuele. 1992. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 35:153-156.
4. Diaz, M., R. Negroni, F. Montero-Gei, L. G. Castro, S. A. Sampaio, D. Borelli, A. Restrepo, L. Franco, J. L. Bran, and E. G. Arathoon. 1992. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin. Infect. Dis. 14(Suppl. 1):68-76.
5. Fernández-Torres, B., I. Inza, and J. Guarro. 2003. In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J. Clin. Microbiol. 41:5209-5211.
6. Ghosh, A., A. Chakrabarti, B. M. Hemanshettar, and P. K. Maity. 2001. In vitro susceptibility pattern of Sporothrix schenckii strains isolated from three centers in India. Indian J. Med. Res. 113:214-220.
7. Ghosh, A., P. K. Maity, B. M. Hemashettar, V. K. Sharma, and A. Chakrabarti. 2002. Physiological characters of Sporothrix schenckii isolates. Mycoses 45:449-454.
8. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42:741-745.
9. Kauffman, C. A., R. Hajjeh, and S. W. Chapman. 2000. Practice guidelines for the management of patients with sporotrichosis. Clin. Infect. Dis. 30:684-687.
10. Kauffman, C. A., P. G. Pappas, D. S. McKinsey, R. A. Greenfield, J. R. Perfect, G. A. Cloud, C. J. Thomas, and W. E. Dismukes. 1996. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. 22:46-50.
11. Kohler, L. M., P. C. Fialho, R. C. Hahn, and J. Soares. 2004. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J. Clin. Microbiol. 42:4319-4320.
12. Lopes, J. O., S. H. Alves, C. R. Mari, L. M. Brum, J. B. Westphalen, M. J. Altermann, and F. B. Prates. 1999. Epidemiologia da esporotricose na região central do Rio Grande do Sul. Rev. Soc. Bras. Med. Trop. 32:541-545.
13. Lortholary, O., D. W. Denning, and B. Dupont. 1999. Endemic mycoses: a treatment update. J. Antimicrob. Chemother. 43:321-331.
14. McGinnis, M. R., N. Nordoff, R. K. Li, L. Pasarell, and D. W. Warnock. 2001. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med. Mycol. 39:369-371.
15. Morishita, N., K. Yamazaki, J. Ninomiya, T. Hamaguchi, Y. Sei, and I. Takiuchi. 2001. A case of lymphocutaneous sporotrichosis. Jpn. J. Med. Mycol. 42:149-154.
16. Morris-Jones, R. 2002. Sporotrichosis. Clin. Exp. Dermatol. 27:427-431.
17. Nakai, T., J. Uno, F. Ikeda, S. Tawara, K. Nishimura, and M. Miyaji. 2003. In vitro antifungal activity of micafungina (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. 47:1376-1381.
18. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Shadomy, S., S. C. White, M. P. Yu, and W. E. Dismukes. 1985. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J. Infect. Dis. 152:1249-1256.
21. Sharkey-Mathis, P. K., C. A. Kauffman, J. R. Graybill, D. A. Stevens, T. S. Hostetler, G. Cloud, and W. E. Dismukes. 1993. Treatment of sporotrichosis with itraconazole. Am. J. Med. 95:279-285.
22. Trilles, L., B. Fernández-Torres, M. dos Santos Lazéra, B. Wanke, and J. Guarro. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42:4815-4817.